News
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
October 14, 2021
“These results suggest that use of D-dimer levels to exclude PE among patients hospitalized with COVID-19 may be inappropriate and have limited clinical utility.”
News
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
![1]()
News
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
September 21, 2021
In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it improved specificity for intermediate-high–risk PE.
News
Study gives bleeding risk estimates for VTE patients on anticoagulants
September 13, 2021
New research provides best available estimates of long-term bleeding risk with different anticoagulants, authors say.
News
Prophylactic anticoagulation tied to lower death rate in COVID
June 18, 2021
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients hospitalized with COVID-19 in Michigan.
News
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
March 16, 2021
“[Chapter one] of the guidelines is devoted to blood pressure measurement ... if [targeting] 120 [mm Hg systolic], the emphasis is on 120 measured properly.”
News
Factor XI inhibitor–based anticoagulation strategies gain ground
November 18, 2020
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
![1]()
News
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
September 1, 2020
“Who’s happy with the HOME-PE trial? I think everybody.” – Dr. Stavros V. Konstantinides
![1]()
News
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
April 21, 2020
Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and reduced rates of VTE and aortic stenosis.
News
Larger absolute rivaroxaban benefit in diabetes: COMPASS
March 29, 2020
The new vascular low dose of rivaroxaban has had a slow start, but these results may stimulate use in patients with diabetes and stable disease.
